Therapeutic agent for respiratory diseases
By using the PPARα agonist pemabelt, the TFEB expression and autophagy process were controlled, and the lesion progression and cell death problems of chronic lung diseases such as COPD and IPF were solved, and effective treatment of COPD and IPF was achieved.
Patent Information
- Application Number
- CN202380030391.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-31
- Filing Date
- 2023-03-30
- Publication Date
- 2024-11-12
AI Technical Summary
Existing agents cannot effectively inhibit the progression of lesions in chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), especially abnormal lung tissue and cell death problems.
(R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] Butyric acid (Pemabelt) is a PPARα agonist and develops a pharmaceutical composition for the treatment of COPD and IPF by controlling the expression and autophagy of TFEB.
Permabel can significantly inhibit lung structural destruction, cellular aging and pulmonary fibrosis caused by smoking exposure, providing new treatment options and therapeutic effects for patients with COPD and IPF.
Smart Images

Figure BDA0005059618020000021 
Figure BDA0005059618020000051 
Figure HDA0005059618030000011
Abstract
Description
Technical Field
[0001] The present invention relates to the treatment of chronic lung diseases such as chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Background Art
[0002] In recent years, the prevalence of chronic lung diseases in the elderly, especially chronic obstructive pulmonary disease (COPD), has become a problem. COPD is defined in pathophysiology as "a progressive development of irreversible airflow obstruction caused by an abnormal inflammatory response to harmful substances." Lesions involved in the pathogenesis of COPD include central airway lesions caused by excessive airway secretion, peripheral airway lesions caused by fixed airway obstruction, and alveolar emphysema lesions. In particular, in the peripheral airways or lung parenchyma, if the symptoms are severe, tissue fragmentation or fibrosis caused by cell death will occur, which is very different from the symptoms of bronchial asthma. It is believed that cell apoptosis is the cause of tissue destruction, and in particular, neutrophil infiltration and the accompanying excessive increase in elastase play an important role.
[0003] As the cause of COPD, the most important factor includes smoking, and smoking cessation guidance as an effective prevention method is gradually gaining attention in daily clinical practice. In addition, other factors can be listed as: genetic factors, airway hyperresponsiveness, lung growth, exposure to harmful substances at work, inhalation of pollutants indoors and outdoors, infection, etc. As a drug administration therapy for COPD, the current situation is to directly apply common asthma treatment drugs such as beta agonists, anticholinergics, xanthine preparations and steroids, but the effect of these drugs is to relieve the symptoms caused by COPD, and these drugs cannot be expected to inhibit the progression of lesions or improve lesions. Therefore, there is a strong desire to develop a drug that can inhibit the abnormalization of lung tissue associated with COPD.
[0004] Recent studies have reported that aging or autophagy is involved in the causes of chronic lung diseases such as COPD and idiopathic pulmonary fibrosis (IPF) (Non-Patent Documents 1 to 3), and it is expected that new treatment methods will be established by controlling them.
[0005] TFEB (Transcription factor EB) is known as a transcription factor that controls autophagy and lysosomal biogenesis, and its expression is regulated by PPARα (Non-patent Documents 4, 5). In fact, Gemfibrozil, known as a PPARα agonist, has been reported to exert its effects on COPD by controlling TFEB (Non-patent Documents 6, 7).
[0006] On the other hand, Patent Document 1 discloses that compounds represented by the following formula (1), their salts or their solvates have a selective PPARα activation effect and are useful as preventive and / or therapeutic drugs for hyperlipidemia, arteriosclerosis, diabetes, diabetic complications (diabetic nephropathy, etc.), inflammation, heart disease, etc., which are not accompanied by weight gain or obesity in mammals including humans.
[0007]
[0008] (Where R 1 and R 2 The same or different, represents a hydrogen atom, a methyl group or an ethyl group; R 3a , R 3b , R 4a and R 4b The same or different, representing hydrogen atoms, halogen atoms, nitro groups, hydroxyl groups, C 1-4 Alkyl, trifluoromethyl, C 1-4 Alkoxy, C 1-4 Alkylcarbonyloxy, di-C 1-4 Alkylamino, C 1-4 Alkylsulfonyloxy, C 1-4 Alkylsulfonyl, C 1-4 Alkylsulfinyl, or C 1-4 Alkylthio, or R 3a With R 3b or R 4a With R 4b X represents an oxygen atom, a sulfur atom or NR 5 (R 5 represents hydrogen atom, C 1-4 Alkyl, C 1-4 Alkylsulfonyl, C 1-4 Alkoxycarbonyl); Y represents an oxygen atom, S(O) l yl (l represents a number 0 to 2), carbonyl, carbonylamino, aminocarbonyl, sulfonylamino, aminosulfonyl, or NH group; Z represents CH or N; n represents a number 1 to 6; m represents a number 2 to 6.)
[0009] However, Patent Document 1 does not describe or teach the effects of these compounds on chronic lung diseases such as COPD and IPF.
[0010] Prior art literature
[0011] Patent Literature
[0012] Patent Document 1: International Publication No. 2005 / 023777
[0013] Non-patent literature
[0014] Non-patent literature 1: Kuwano K et al.: Respir Invest (2016) 54: 397
[0015] Non-patent document 2: Hosaka Y et al.: Inflamm Regener (2021) 41: 29
[0016] Non-patent document 3: Liao SX et al.: Ther Adv Respir Dis (2019) 13: 1 Non-patent document 4: Ghosh A and Pahan K: Pharmacol Res (2016) 103: 144. Non-patent document 5: Settembre C et al.: Nat Cell Biol (2013) 15: 647.
[0017] Non-patent document 6: Bodas M et al.: Antiox Redox Signal (2017) 27(3): 150, Non-patent document 7: Bodas M et al.: Free Rad Biol Med (2019) 131: 81 Summary of the invention
[0018] Technical problem to be solved by the invention
[0019] The object of the present invention is to provide a new therapeutic agent useful for treating chronic lung diseases such as COPD and IPF.
[0020] Technical solutions for solving technical problems
[0021] In order to achieve the above-mentioned purpose, the inventors of the present invention conducted in-depth research and unexpectedly found that the compound disclosed as Example 85 in the above-mentioned Patent Document 1, namely (R)-2-[3-[[N-(Benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid (hereinafter also referred to as "pemafibrate") is useful for treating chronic lung diseases such as COPD and IPF, thereby completing the present invention.
[0022] That is, the present invention provides the following [1] to
[15] .
[0023] [1] A pharmaceutical composition for treating chronic lung disease, comprising a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof.
[0024] [2] The pharmaceutical composition according to [1], wherein the chronic lung disease is chronic obstructive pulmonary disease.
[0025] [3] The pharmaceutical composition according to [1], wherein the chronic lung disease is idiopathic pulmonary fibrosis.
[0026] [4] A therapeutic agent for chronic lung disease, comprising (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof as an active ingredient.
[0027] [5] The therapeutic agent according to [4], wherein the chronic lung disease is chronic obstructive pulmonary disease.
[0028] [6] The therapeutic agent according to [4], wherein the chronic lung disease is idiopathic pulmonary fibrosis.
[0029] [7] A method for treating chronic lung diseases, comprising administering (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof to a patient in need thereof.
[0030] [8] The treatment method described in [7], wherein the chronic lung disease is chronic obstructive pulmonary disease.
[0031] [9] The method of treatment as described in [7], wherein the chronic lung disease is idiopathic pulmonary fibrosis.
[0032]
[10] A (R)-2-[3-[[N-(Benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof for use in treating chronic lung diseases.
[0033]
[11] (R)-2-[3-[[N-(Benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof as described in
[10] , wherein the chronic lung disease is chronic obstructive pulmonary disease.
[0034]
[12] (R)-2-[3-[[N-(Benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof as described in
[10] , wherein the chronic lung disease is idiopathic pulmonary fibrosis.
[0035]
[13] Use of (R)-2-[3-[[N-(Benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, its salt, or its solvate in the manufacture of a pharmaceutical composition for treating chronic lung disease.
[0036]
[14] The use as described in
[13] , wherein the chronic lung disease is chronic obstructive pulmonary disease.
[0037]
[15] The use as described in
[13] , wherein the chronic lung disease is idiopathic pulmonary fibrosis.
[0038] Effects of the Invention
[0039] The present invention provides a new therapeutic agent useful for treating chronic lung diseases such as COPD and / or IPF. According to the present invention, a new treatment option can be provided for patients with chronic lung diseases such as COPD and IPF for whom the effects of existing therapeutic agents cannot be fully confirmed, and for patients with chronic lung diseases such as COPD and IPF for whom existing therapeutic agents are difficult to use. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 The effect of pemafibrate on the induction of TEFB expression in human airway epithelial cells is shown.
[0041] Figure 2 Showing the effect of pemafibrate on cigarette smoking stimulus-induced cellular senescence.
[0042] Figure 3 The effect of pemafibrate on the induction of TEFB expression in a smoke exposure COPD model is shown.
[0043] Figure 4 The effect of pemafibrate on cell distribution in bronchoalveolar lavage fluid in a smoke-exposed COPD model is shown.
[0044] Figure 5 Tissue images showing the effect of pemafibrate on emphysema in a smoke-exposed COPD model.
[0045] Figure 6 The effect of pemafibrate on emphysema in a smoke-exposed COPD model is shown.
[0046] Figure 7 Showing the effect of pemafibrate on cellular senescence in a smoke-exposed COPD model.
[0047] Figure 8 The effect of pemafibrate in the Bleomycin model of pulmonary fibrosis is shown. DETAILED DESCRIPTION
[0048] The (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid (pemafibrate) used in the present invention is represented by the following chemical formula (A):
[0049]
[0050] The compound can be manufactured according to the method described in International Publication No. 2005 / 023777 pamphlet, etc., for example. In addition, it can also be formulated according to the method described in the literature. Furthermore, the preparation containing pemafibrate is approved as a hyperlipidemia therapeutic agent "Parmodia (registered trademark) tablet (PARMODIA)" in Japan, and the "Parmodia tablet" can also be used.
[0051] In addition, in one embodiment of the present invention, a salt or solvate of pemafibrate can also be used. Salts and solvates can be manufactured by conventional methods. As a salt of pemafibrate, there is no particular limitation as long as it is a pharmaceutically acceptable salt, for example, it can be listed as: alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; organic alkali salts such as ammonium salts and trialkylamine salts; inorganic acid salts such as hydrochlorides and sulfates; organic acid salts such as acetates, etc. As a solvate of pemafibrate or its salt, it includes hydrates, alcoholates (for example, ethanolates), etc.
[0052] As shown in the examples described later, pemafibrate increases the expression of TFEB in the lungs of a mouse chronic obstructive pulmonary disease (COPD) model, and suppresses the destruction of lung structure caused by smoking exposure. In addition, it suppresses the rise of macrophages in the bronchoalveolar lavage fluid caused by smoking exposure, and suppresses cell aging. In addition, further, pemafibrate suppresses the increase in the amount of hydroxyproline in the lungs of the bleomycin-induced mouse pulmonary fibrosis model known as an animal model of idiopathic pulmonary fibrosis (IPF). Therefore, in one embodiment of the present invention, by administering a pharmaceutical composition comprising a therapeutically effective amount of pemafibrate, its salt, or their solvates to patients with chronic lung diseases such as COPD, IPF, chronic lung diseases such as COPD, IPF can be treated.
[0053] In the present invention, chronic obstructive pulmonary disease (COPD) is defined as "a lung disease caused by long-term inhalation or exposure to harmful substances, mainly cigarette smoke, which manifests as airflow obstruction in respiratory function tests. Airflow obstruction is caused by the combined involvement of peripheral airway lesions and emphysematous lesions in various proportions. Clinically, it manifests as slowly progressive dyspnea during work and chronic cough / sputum, but there are also cases where these symptoms are milder" (Edited by the COPD Guidelines 5th Edition Production Committee of the Japanese Respiratory Society: Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease) 2018 5th Edition. 2018).
[0054] In addition, idiopathic pulmonary fibrosis (IPF) is a type of "idiopathic interstitial pneumonia" and is a "disease with a poor prognosis that undergoes a chronic and progressive course, progresses to high fibrosis, and causes irreversible honeycombing" (Diagnosis and Treatment Guidelines for Idiopathic Interstitial Pneumonia: Japanese Respiratory Society Diffuse Lung Disease Diagnosis and Treatment Guidelines Development Committee Ministry of Health, Labor and Welfare Scientific Research Specific Disease Countermeasures Project Diffuse Lung Disease Research Group).
[0055] Symptoms of these chronic lung diseases include dry cough (cough without sputum), excessive sputum, shortness of breath, crepitus, clubbing of fingers, etc., but are not limited to these symptoms.
[0056] The diagnosis of COPD and IPF is performed, for example, based on smoking history, clinical symptoms / signs, blood tests (oxygen content, serum markers, etc.), respiratory function tests (spirometry, etc.), and imaging diagnosis (chest X-ray, high-resolution CT, etc.). Lung biopsy may also be performed.
[0057] In the present invention, the treatment of chronic lung diseases such as COPD and IPF refers to one or more selected from the group consisting of improving respiratory function, alleviating the above-mentioned various symptoms, and inhibiting the progression of pulmonary fibrosis.
[0058] In one embodiment of the present invention, the pharmaceutical composition comprising pemafibrate, its salt or a solvate thereof can be prepared into dosage forms such as tablets, capsules, granules, powders, lotions, ointments, injections, inhalants, suppositories, etc. using other pharmaceutically acceptable carriers. These preparations can be prepared by known methods.
[0059] Examples of pharmaceutically acceptable carriers include excipients, disintegrants, binders, lubricants, plasticizers, glidants, diluents, solubilizers, suspending agents, isotonic agents, pH adjusters, buffers, stabilizers, coating agents, colorants, flavoring agents, and odor correctors.
[0060] In one embodiment of the present invention, from the viewpoint of chronic lung disease as the object, the pharmaceutical composition comprising pemafibrate, its salt, or their solvates is preferably in the form of an inhaler. The inhaler is not particularly limited and can be appropriately selected from inhalation powders, inhalation liquids, inhalation aerosols, etc. When using the inhaler of the present invention, for inhalation administration, a suitable apparatus or device can be used, or it can be filled into a container having an inhalation apparatus.
[0061] In one embodiment of the present invention, the therapeutically effective amount and the number of administrations of pemafibrate, its salt or their solvates, although different according to the patient's weight, age, sex, symptoms, etc., can be appropriately set by those skilled in the art. For example, usually in the case of adults, pemafibrate can be administered 1 to 3 times a day at 0.05 mg to 0.8 mg, preferably 1 to 2 times a day at 0.2 mg to 0.4 mg, more preferably 1 or 2 times a day at 0.1 mg to 0.8 mg.
[0062] The subjects to whom the pharmaceutical composition of the present invention is administered include people who wish or need treatment for chronic lung diseases such as COPD and IPF, and preferably people for whom existing therapeutic agents do not provide sufficient effects or for whom existing therapeutic agents are difficult to use.
[0063] Hereinafter, the present invention will be further described in detail by way of examples, but these examples do not limit the present invention.
[0064] Example
[0065] Example 1: Induction of TEFB expression in human airway epithelial cells
[0066] The effect of pemafibrate was studied according to the procedure described in the reference (Araya J, et al.: Autophagy (2019) 15(3): 510). That is, human airway epithelial cells (BEAS2B) were cultured in a medium supplemented with 10 nM and 100 nM pemafibrate for 24 hours and compared with a control group (0 nM).
[0067] The results are shown in Figure 1 (Mean±SE, n=3). It was confirmed that TFEB expression increased in a pemafibrate-dose-dependent manner, and the ratio of TFEB expression to ACTB expression as a control was examined, and it was found that there was a significant difference compared with the control group (*: p<0.05, analysis of variance (ANOVA) and Tukey post hoc test).
[0068] Example 2: Effects on smoking-induced cellular senescence
[0069] The effect of pemafibrate was studied according to the procedure described in the reference (Saito N, et al.: J Immunol (2019) 202: 1428). That is, cultured human airway epithelial cells (HBEC) were cultured in a medium supplemented with 10nM to 100nM pemafibrate together with 1% CSE (cigarette smoke extract) for 24 hours and compared with a control group (0nM).
[0070] The results are shown in Figure 2(Mean ± standard error, n = 4). The expression of p21, an indicator of cell apoptosis, increased due to CSE stimulation, but was dose-dependently inhibited by pemafibrate. When the ratio of its expression level to that of the control ACTB was studied, it was found that a significant difference was observed for pemafibrate above 20 nM compared with the control group (*: p < 0.05, analysis of variance and Tukey post hoc test). This result confirmed the inhibitory effect of pemafibrate on cell senescence.
[0071] Example 3: Effects on COPD Model Exposed to Smoking
[0072] The effect of pemafibrate was studied according to the procedure described in the reference (Araya J, et al.: Autophagy (2019) 15 (3): 510). That is, C57BL / 6J mice were exposed to smoke five times a week for six months using an exposure inhalation system for small animals. The mice in the normal diet group (Ctrl) and the 0.0003w / w% pemafibrate mixed feed group (Pema) were divided into a room air group (RA) and a smoke exposure group (CS), for a total of four groups.
[0073] The results are shown in Figure 3 to Figure 7 First, the lungs were removed from the room air group (RA) after administration and homogenized to evaluate TFEB expression. The results showed that TFEB expression increased in the pemafibrate-administered group ( Figure 3 : Mean ± standard error, n = 3). Then, bronchoalveolar lavage fluid was collected and cells were evaluated. The results showed that the increase in macrophages due to cigarette smoke exposure (CS) was suppressed in the pemafibrate-administered group ( Figure 4 : Mean ± standard error, n = 5-8). In addition, the alveolar diameter was measured to evaluate the degree of emphysema, and the results showed that the destruction of lung structure caused by smoking exposure (CS) was suppressed in the pemafibrate-administered group ( Figure 5 : Mean ± SE, n = 5-8 (**: p < 0.01, ***: p < 0.001, ANOVA and Tukey post hoc test) and Figure 6 ). Furthermore, cell senescence was evaluated, and the results showed that cell senescence caused by cigarette smoke exposure (CS) was suppressed in the pemafibrate-administered group ( Figure 7 : mean ± standard error, n = 4 to 6).
[0074] Example 4: Effects on the Bleomycin Pulmonary Fibrosis Model
[0075] The effects of Pemabet were studied according to the procedures described in the reference (Kadota T et al. J Extracell Vesicles. 2021Aug; 10(10): e12124). That is, C57BL / 6J mice were divided into 4 groups based on the presence or absence of bleomycin administration (BLM / NS) and the presence or absence of Pemabet administration (Ctrl / Pema). For the BLM group, bleomycin (2.5U) administration induced fibrosis, and Pemabet was administered in the form of 0.0003w / w% mixed feed from the 7th day of BLM administration. The lungs were removed on the 21st day after BLM administration, and the amount of hydroxyproline in the lungs was measured.
[0076] The results are shown in Figure 8 (mean ± standard error, n = 3) It was confirmed that hydroxyproline, which is a fibrosis index, increased by bleomycin administration but was suppressed by pemafibrate administration.
[0077] In summary, Examples 1 to 3 show that pemafibrate has an effect of inhibiting cell senescence and is useful for the treatment of COPD. In addition, Example 4 shows that pemafibrate is useful for the treatment of IPF.
[0078] Industrial Applicability
[0079] The present invention was completed based on the first discovery that pemafibrate has a therapeutic effect on COPD and IPF, and is useful as a drug for treating chronic lung diseases.
Claims
1. A pharmaceutical composition for treating chronic lung disease, Features: The invention comprises a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof or a solvate thereof.
2. The pharmaceutical composition according to claim 1, Features: Chronic lung disease is chronic obstructive pulmonary disease.
3. The pharmaceutical composition according to claim 1, Features: The chronic lung disease is idiopathic pulmonary fibrosis.
4. A method for treating chronic lung disease, Features: An effective amount of (R)-2-[3-[[N-(Benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof or a solvate thereof is administered to a patient in need thereof.
5. The method of treatment according to claim 4, Features: Chronic lung disease is chronic obstructive pulmonary disease.
6. The method of treatment according to claim 4, Features: The chronic lung disease is idiopathic pulmonary fibrosis.
7. (R)-2-[3-[[N-(Benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof, Features: Used to treat chronic lung disease.
8. (R)-2-[3-[[N-(Benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof according to claim 7, Features: Chronic lung disease is chronic obstructive pulmonary disease.
9. (R)-2-[3-[[N-(Benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof according to claim 7, Features: The chronic lung disease is idiopathic pulmonary fibrosis.
10. Use of (R)-2-[3-[[N-(Benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, its salt or its solvate in the manufacture of a pharmaceutical composition for treating chronic lung disease.
11. The use according to claim 10, Features: Chronic lung disease is chronic obstructive pulmonary disease.
12. The use according to claim 10, Features: The chronic lung disease is idiopathic pulmonary fibrosis.
